Gene expression profiles and pathway enrichment analysis of human osteosarcoma cells exposed to sorafenib.

about

Gene expression profiles and pathway enrichment analysis of human osteosarcoma cells exposed to sorafenib.

Item

http://www.wikidata.org/entity/Q53823554

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Gene expression profiles and p ...... ma cells exposed to sorafenib.

@en

Gene expression profiles and p ...... ma cells exposed to sorafenib.

@nl

type

Item

label

Gene expression profiles and p ...... ma cells exposed to sorafenib.

@en

Gene expression profiles and p ...... ma cells exposed to sorafenib.

@nl

prefLabel

Gene expression profiles and p ...... ma cells exposed to sorafenib.

@en

Gene expression profiles and p ...... ma cells exposed to sorafenib.

@nl

P1476

Gene expression profiles and p ...... ma cells exposed to sorafenib.

@en

P2093

Haoyu Tang

http://www.w3.org/2001/XMLSchema#string

Jun Zhu

http://www.w3.org/2001/XMLSchema#string

Junquan Chen

http://www.w3.org/2001/XMLSchema#string

Yongping Li

http://www.w3.org/2001/XMLSchema#string

Yue Pan

http://www.w3.org/2001/XMLSchema#string

Zhehao Dai

http://www.w3.org/2001/XMLSchema#string

P2860

The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes

KEGG: kyoto encyclopedia of genes and genomes

The Gene Ontology (GO) project in 2006

DAVID: Database for Annotation, Visualization, and Integrated Discovery

Review of Osteosarcoma and Current Management

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

AP-1: a double-edged sword in tumorigenesis

Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).

Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.

P304

860-867

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/2211-5463.12428

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29744300

http://www.w3.org/2001/XMLSchema#string

P932

5929930

http://www.w3.org/2001/XMLSchema#string